Verheul, H.M.W., Hoekman, K., Jorna, A.S., Smit, E.F., and Pinedo, H.M. (2000) Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. The Oncologist, 5 (suppl 1), 45-50. doi:10.1634/theoncologist.5-suppl_1-45

has been cited by the following article:

• TITLE: The diagnostic significance and the assessment of the value of vascular endothelial growth factor as a marker for success of chemical pleurodesis in malignant pleural effusion

  AUTHORS: Dalokay Kilic, Alper Findikcioglu, Goknur Alver, Tolga Tatar, Hakan Akbulut, Ahmet Hatipoglu

  KEYWORDS: Malignant pleural effusion, pleural effusion, chemical pleurodesis, vascular endothelial growth factor

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.4 No.3, March 8, 2011

  ABSTRACT: Differential diagnosis of pleural effusion is an important issue, since the treatment modalities and prognosis strictly depend on early and correct diagnosis of the underlying etiology. We assessed the efficacy of vascular endothelial growth factor (VEGF) in the differential diagnosis of patients with malignant and non-malignant pleural diseases. And also is assessed of the VEGF as a marker for success of chemical pleurodesis in malignant pleural effusion. Pleural effusions of 40 patients with a mean age of 55 (range, 26 to 78 years) were examined. A total of 20 patients had malignant pleural effusion; malignant mesothelioma (n=7), lung cancer (n=5) and metastatic malignancies (n=8). Twenty patients had benign pleural effusion; fibrinous pleuritis (n=6), tuberculosis (n=3) empyema (n=5), congestive heart failure (n=3), and acute pancreatitis (n=3). Definitive diagnosis was obtained in all cases with blind or open pleural biopsy, and cytological examination. VEGF levels were determined by enzyme-linked immunosorbent assay. The VEGF level of pleural effusion was comparably higher in the malignant group. The mean level of VEGF in patients with malignant pleural effusions (21.7 ± 1.8 ng/ml) was significantly (P